 |
24 Diseases |  |
0 Trials |
|
0 Trials |  |
4 News |  |
- | JI-101 / Jubilant LifeSciences
Journal: Kinome multigenic panel identified novel druggable EPHB4-V871I somatic variant in high-risk neuroblastoma. (Pubmed Central) - Apr 30, 2021
The use of two EPHB4 inhibitors, JI-101 and NVP-BHG712, was able to rescue the phenotype driven by the variant. Our study suggested that EPHB4 is a promising therapeutic target in high-risk NB.
- JI-101 / Jubilant LifeSciences
Trial termination, Metastases: Study of JI-101 in Patients With Advanced Low Grade Endocrine Tumors, Ovarian Cancers or K-RAS Mutant Colon Cancers (clinicaltrials.gov) - Aug 12, 2012
P1/2, N=19, Terminated, Sponsor: University of Utah
Our study suggested that EPHB4 is a promising therapeutic target in high-risk NB. Active, not recruiting --> Terminated; Lack of drug efficacy
- JI-101 / Jubilant LifeSciences
Enrollment change, Metastases: Study of JI-101 in Patients With Advanced Low Grade Endocrine Tumors, Ovarian Cancers or K-RAS Mutant Colon Cancers (clinicaltrials.gov) - Aug 12, 2012
P1/2, N=19, Terminated, Sponsor: University of Utah
Active, not recruiting --> Terminated; Lack of drug efficacy N=40 --> 19
- | JI-101 / Jubilant LifeSciences
Trial completion, Metastases: A Phase 1/2, Open-Label, Dose-Escalation Study of JI-101, in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Apr 18, 2012
P1/2, N=18, Completed, Sponsor: Jubilant Innovation Ltd.
N=40 --> 19 Active, not recruiting --> Completed